Press release
Amplified Sciences Secures Exclusive Patent License from UCSF for Cutting-Edge Diagnostic Technology
Dr. Kimberly Kirkwood (left) and Dr. Charles Craik (right), professors at UCSF, using Amplified Sciences' BioMatra.
PanCystPro helps risk stratify patients diagnosed with pancreatic cystic lesions who are at higher risk of developing pancreatic cancer. This multi-analyte test leverages a novel protease turnover assay for gastricsin, an enzyme that is atypically found in the pancreas thus providing biological insight into the cyst's potential for malignancy. The assay represents a new method of targeting enzymes as biomarkers in precision medicine.
The gastricsin assay technology originated in the laboratory of Charles Craik, PhD, Professor of Pharmaceutical Chemistry at UCSF, whose research team was instrumental in its discovery and development. Dr. Craik has produced groundbreaking research on the role of enzymes in diagnosing disease and as potential therapeutic targets. "We are excited to see our work move from the research bench to the clinic," said Dr. Craik. "By partnering with Amplified Sciences, we are able to translate this scientific innovation into real-world impact for patients."
"Amplified Sciences' test represents an important leap forward in our ability to make informed clinical decisions in the management of patients diagnosed with pancreatic cystic lesions, a known pre-cursor for pancreatic cancer," said Dr. Kimberly Kirkwood, Professor of Surgery in the Division of Surgical Oncology. "We are thrilled to see our early work on discovery of enzymes in pre-cancerous lesions translate into clinical tests that are now available to our patients. Having access to highly accurate tests like those developed by Amplified Sciences allows physicians to better identify patients at higher pancreatic cancer risk who would benefit from surgery while avoiding unnecessary procedures for those at very low risk."
PanCystPro, Amplified Sciences' first test has undergone the testing and validation as a lab developed test and is offered in their CLIA lab in Irvine, California.
The exclusive license agreement from UCSF exemplifies UCSF's commitment to advancing health care solutions through strategic partnerships with industry leaders. To secure the license and create a win-win partnership, Amplified Sciences worked closely with UCSF's Innovation Ventures, which leads business development and licensing efforts on behalf of UCSF.
"We are thrilled to partner with UCSF in bringing a novel enzymatic activity detection method to life on the Amplified Sciences' BioMatra platform," said Diana Caldwell, CEO of Amplified Sciences. "Our partnership goes back several years including clinical research collaboration leveraging Dr. Kirkwood's expertise in the field and critical pancreatic cyst biobank resources. And long before that, my co-founder Jo Davisson worked with Charly at UCSF in the same department early in their careers."
The company is currently enrolling sites in a Clinical Utility study and plans to launch an Early Access Program later this year, with UCSF as the first healthcare system able to offer the test to patients.
Caldwell states, "Our goal is to make PanCystPro accessible, ensuring that patients and healthcare providers receive timely answers regarding their potential risk of pancreatic cancer. The UCSF partnership enables us to make progress towards our vision of a world transformed by earlier and more precise disease detection."
About Amplified Sciences
Amplified Sciences is a life science diagnostics company focused on providing innovative diagnostic tests that enable earlier detection, risk stratification, and monitoring of serious diseases. BioMatraTM, the company's ultrasensitive optical reporter platform leverages technology licensed from Purdue University. Its headquarters is in West Lafayette, Indiana and the CLIA certified clinical lab is located in Irvine, California. To learn more about Amplified Sciences, visit https://amplifiedsciences.com/.
About UCSF
The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF's primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at https://www.ucsf.edu/ or see our Fact Sheet at https://www.ucsf.edu/sites/default/files/2025-03/UCSF-General-Fact-Sheet-March-2025.pdf.
About UCSF Innovation Ventures
Innovation Ventures works closely with UCSF's researchers, faculty, staff and students to protect, develop, and commercialize UCSF innovation. To facilitate commercialization, Innovation Ventures establishes industry partnerships, negotiates and executes licensing agreements, and starts new companies. Learn more at https://innovation.ucsf.edu/.
Media Asset:
Photo by Sean Karlin, UCSF
Media Contact
Diana Caldwell
diana.caldwell@amplifiedsci.com
3000 Kent Avenue., Suite 1950
West Lafayette, IN 47906
https://amplifiedsciences.com/contact-us/
Diana Caldwell, CEO and Co-Founder
diana.caldwell@amplifiedsci.com
Amplified Sciences is a diagnostics company committed to providing answers for clinicians diagnosing, treating and monitoring challenging diseases. The company is built on an innovative and proprietary ultra-sensitive optical reporter platform technology leveraging novel dyes supported with composition of matter IP. Our leadership team has the product development expertise and commercial acumen to identify, innovate, and commercialize a diversified portfolio of diagnostic products in markets with unmet clinical needs. Our team's expertise in research and product development combined with commercial stage experience fuels our ability to provide meaningful solutions that will impact standard of care.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amplified Sciences Secures Exclusive Patent License from UCSF for Cutting-Edge Diagnostic Technology here
News-ID: 4078686 • Views: …
More Releases for UCSF
Prostate Cancer Nuclear Medicine Diagnostics Market With Leading Players like Bl …
Prostate cancer is cancer affecting the prostate glands in men. Prostate cancer is the second most common cancer after skin cancer in men. Several common factors accountable for the onset of prostate cancer are old age, family history, and race. Nuclear medicine is imaging that requires radioactive materials. It is a useful method to detect and also treat prostate cancer and helps radiologists to conclude the stage of cancer.
An off-the-shelf…
Bioartificial Kidney Market 2020-28 a step closer towards, research and developm …
The bioartificial kidney is a compact, surgically implanted, free-standing device to treat kidney failure. It performs the vast majority of the biological functions of the natural kidney. Hemodialysis is a procedure where a dialysis machine and a special filter called an artificial kidney, or a dialyzer, are used to clean your blood.
A new business intelligence report released by Report Consultant titled "Global Bioartificial Kidney Market" is designed covering micro level…
John A. Emery MD Promotes His Medical Memoir - A Surgeon’s Life With Bipolar D …
John A. Emery MD Promotes His Medical Memoir - A Surgeon’s Life With Bipolar Disorder
John A. Emery MD is pleased to announce the promotion of his medical memoir, A Surgeon’s Life With Bipolar Disorder.
Dr. Emery presents a proactive memoir, which discusses pipolar disorder and how this disease affected his life before and after the diagnosis at age 39.
Dr. Emery has had many unique experiences including a childhood in West Virginia,…
Medical Holographic Display Market to Reflect Impressive Growth Rate of 27% by 2 …
The Medical holographic display Market is expected to register a CAGR of about 27%, during the forecast period, 2018 to 2023. Holography is a method of producing a three-dimensional image of an object by recording a split beam of light from a laser. The coherent light from the laser is reflected from an object and combined at the film with light from a reference beam. This recorded interference pattern enables…
Medical Holography Market Size, Share, Outlook and Forecast Report with Top Key …
The Global Medical Holography Market 2018 to 2024 renders deep perception of the key regional market status of the Medical Holography Industry on a global level that primarily aims the core regions which comprises of continents like North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa and the key countries such as U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore,…
Medical Holographic Display Market to Witness Huge Growth by 2023: Key Players - …
Global Medical Holographic Display Market Highlights
The Medical holographic display Market is expected to register a CAGR of about 27%, during the forecast period, 2018 to 2023. Holography is a method of producing a three-dimensional image of an object by recording a split beam of light from a laser. The coherent light from the laser is reflected from an object and combined at the film with light from a reference beam.…
